MiMedx Group Inc (MDXG) : During the past 4 weeks, traders have been relatively bearish on MiMedx Group Inc (MDXG), hence the stock is down -3.13% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.17% relative to the S&P 500. The 4-week change in the price of the stock is -3.34% and the stock has fallen -0.82% in the past 1 week.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 3.03% and the fifty day Moving Average is 5.55%. MiMedx Group, Inc. has dropped 8.93% during the last three month period . Year-to-Date the stock performance stands at -22.73%.
MiMedx Group Inc (MDXG) : Average target price received by MiMedx Group Inc (MDXG) is $11.6 with an expected standard deviation of $1.52. The most aggressive target on the stock is $13, whereas the most downbeat target is $9. 5 financial analysts are currently covering the stock.
MiMedx Group Inc (NASDAQ:MDXG): stock turned positive on Friday. Though the stock opened at $7.23, the bulls momentum made the stock top out at $7.29 level for the day. The stock recorded a low of $7.1 and closed the trading day at $7.24, in the green by 0.70%. The total traded volume for the day was 371,013. The stock had closed at $7.19 in the previous days trading.
MiMedx Group, Inc. (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Companys biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program, mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant, which is referred as an allograft. MiMedx is the supplier of amniotic tissue, having supplied over 350,000 allografts for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.